Table 4. Characteristics of studies evaluating the impacts of cannabis use in individuals with end-stage cancer.

Number of studies	Designs	Primary studies
		Cannabis use type	Funding
32	Overviews of reviews: 4 (in 5 publications) [32–36]	Medical, overseen by physician: 14 [63, 64, 68, 70, 71, 74–77, 81, 85, 98, 133, 152]	Non-industry: 5 [63, 64, 68, 74, 75]
	Systematic review: 12 [39, 41, 45, 46, 50–52, 54–58]	Mixed use: 1 [138]	Industry: 4 [70, 76, 133]
	RCTs: 11 [63, 64, 68, 70, 71, 74–77, 81, 85]	Not reported/Unclear: 1 [161]	Not funded: 1 [85]
	Prospective cohort: 3 [98, 133, 161]		Not reported: 6 [71, 77, 98, 138, 152, 161]
	Retrospective cohort: 1 [152]
	Cross-sectional: 1 [138]